메뉴 건너뛰기




Volumn 46, Issue 5, 2007, Pages 607-615

Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: Collaborative analysis of cohorts of HIV-1-infected patients

(776)  Sterne, Jonathan A C a   May, Margaret b   Sabin, Caroline b   Phillips, Andrew b   Costagliola, Dominique b   Chêne, Geneviève b   Justice, Amy C b   De Wolf, Frank b   Hogg, Robert b   Battegay, Manuel b   Monforte, Antonella D'Arminio b   Fätkenheuer, Gerd b   Staszewski, Schlomo b   Gill, John b   Casabona, Matthias Egger Jordi b   Dabis, Francxois b   Egger, Matthias b   Kitahata, Mari b   Ledergerber, Bruno b   Leport, Catherine b   more..

d INSERM   (France)

Author keywords

AIDS; CD4 counts; Highly active antiretroviral therapy; HIV; Prognosis; Substance abuse (intravenous)

Indexed keywords

CD4 ANTIGEN; ENFUVIRTIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

EID: 36549004647     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (46)

References (31)
  • 1
    • 0442268112 scopus 로고    scopus 로고
    • A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
    • Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
    • (1997) N Engl J Med. , vol.337 , pp. 725-733
    • Hammer, S.M.1    Squires, K.E.2    Hughes, M.D.3
  • 2
    • 9844238154 scopus 로고    scopus 로고
    • Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study
    • Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ. 1997;315:1194-1199.
    • (1997) BMJ , vol.315 , pp. 1194-1199
    • Egger, M.1    Hirschel, B.2    Francioli, P.3
  • 3
    • 0033537620 scopus 로고    scopus 로고
    • Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens
    • Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ. 1999; 160:659-665.
    • (1999) CMAJ , vol.160 , pp. 659-665
    • Hogg, R.S.1    Yip, B.2    Kully, C.3
  • 4
    • 0038162585 scopus 로고    scopus 로고
    • Decline in the AIDS and death rates in the EuroSIDA study: An observational study
    • Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003; 362:22-29.
    • (2003) Lancet , vol.362 , pp. 22-29
    • Mocroft, A.1    Ledergerber, B.2    Katlama, C.3
  • 5
    • 23044496716 scopus 로고    scopus 로고
    • Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: A prospective cohort study
    • Sterne JA, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366:378-384.
    • (2005) Lancet , vol.366 , pp. 378-384
    • Sterne, J.A.1    Hernan, M.A.2    Ledergerber, B.3
  • 6
    • 0037072066 scopus 로고    scopus 로고
    • Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies
    • Egger M, May M, Chêne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
    • (2002) Lancet , vol.360 , pp. 119-129
    • Egger, M.1    May, M.2    Chêne, G.3
  • 7
    • 0041327811 scopus 로고    scopus 로고
    • Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: Analysis of prospective studies
    • Chêne G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003;362:679-686.
    • (2003) Lancet , vol.362 , pp. 679-686
    • Chêne, G.1    Sterne, J.A.2    May, M.3
  • 8
    • 4344585578 scopus 로고    scopus 로고
    • Development and validation of a prognostic model for survival time data: Application to prognosis of HIV positive patients treated with antiretroviral therapy
    • May M, Royston P, Egger M, et al. Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. Stat Med. 2004;23: 2375-2398.
    • (2004) Stat Med. , vol.23 , pp. 2375-2398
    • May, M.1    Royston, P.2    Egger, M.3
  • 9
    • 34248589717 scopus 로고    scopus 로고
    • Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: Collaborative analysis of prospective studies
    • May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21:1185-1197.
    • (2007) AIDS , vol.21 , pp. 1185-1197
    • May, M.1    Sterne, J.A.2    Sabin, C.3
  • 10
    • 33745632904 scopus 로고    scopus 로고
    • Smoothing hazard rate
    • In: Armitage P, Colton T, eds. 2nd ed. Chichester, UK: Wiley
    • Wang J-L. Smoothing hazard rate. In: Armitage P, Colton T, eds. Encyclopedia of Biostatistics. 2nd ed. Chichester, UK: Wiley; 2005: 4986-4997.
    • (2005) Encyclopedia of Biostatistics , pp. 4986-4997
    • Wang, J.-L.1
  • 11
    • 0034657861 scopus 로고    scopus 로고
    • Bootstrap confidence intervals: When, which, what? A practical guide for medical statisticians
    • Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med. 2000;19:1141-1164.
    • (2000) Stat Med. , vol.19 , pp. 1141-1164
    • Carpenter, J.1    Bithell, J.2
  • 12
    • 9844224474 scopus 로고    scopus 로고
    • Pre-AIDS mortality from natural causes associated with HIV disease progression: Evidence from the European Seroconverter Study among injecting drug users
    • Prins M, Hernandez AI, Brettle RP, et al. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users. AIDS. 1997; 11:1747-1756.
    • (1997) AIDS , vol.11 , pp. 1747-1756
    • Prins, M.1    Hernandez, A.I.2    Brettle, R.P.3
  • 13
    • 15844379887 scopus 로고    scopus 로고
    • Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003
    • Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med. 2005;6:99-106.
    • (2005) HIV Med. , vol.6 , pp. 99-106
    • Krentz, H.B.1    Kliewer, G.2    Gill, M.J.3
  • 14
    • 33745078633 scopus 로고    scopus 로고
    • Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion
    • Smit C, Geskus R, Walker S, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS. 2006;20:741-749.
    • (2006) AIDS , vol.20 , pp. 741-749
    • Smit, C.1    Geskus, R.2    Walker, S.3
  • 15
    • 0027252665 scopus 로고
    • Rising HIV-related mortality in young Americans
    • Vermund SH. Rising HIV-related mortality in young Americans. JAMA. 1993;269:3034-3035.
    • (1993) JAMA , vol.269 , pp. 3034-3035
    • Vermund, S.H.1
  • 16
    • 85062055676 scopus 로고    scopus 로고
    • Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study
    • Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632-1641.
    • (2006) Arch Intern Med. , vol.166 , pp. 1632-1641
    • Weber, R.1    Sabin, C.A.2    Friis-Moller, N.3
  • 17
    • 0142120650 scopus 로고    scopus 로고
    • Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users
    • Wood E, Montaner JS, Yip B, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ. 2003;169:656-661.
    • (2003) CMAJ , vol.169 , pp. 656-661
    • Wood, E.1    Montaner, J.S.2    Yip, B.3
  • 18
    • 20044391208 scopus 로고    scopus 로고
    • Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: Emerging role of hepatitis and cancers, persistent role of AIDS
    • Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2005;34:121-130.
    • (2005) Int J Epidemiol. , vol.34 , pp. 121-130
    • Lewden, C.1    Salmon, D.2    Morlat, P.3
  • 19
    • 0034908886 scopus 로고    scopus 로고
    • Study of 2708 heroin-related deaths in north-eastern Italy 1985-98 to establish the main causes of death
    • Quaglio G, Talamini G, Lechi A, et al. Study of 2708 heroin-related deaths in north-eastern Italy 1985-98 to establish the main causes of death. Addiction. 2001;96:1127-1137.
    • (2001) Addiction. , vol.96 , pp. 1127-1137
    • Quaglio, G.1    Talamini, G.2    Lechi, A.3
  • 20
    • 8444253250 scopus 로고    scopus 로고
    • Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy
    • Smith CJ, Sabin CA, Youle MS, et al. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis. 2004;190:1860-1868.
    • (2004) J Infect Dis. , vol.190 , pp. 1860-1868
    • Smith, C.J.1    Sabin, C.A.2    Youle, M.S.3
  • 21
    • 10744227881 scopus 로고    scopus 로고
    • CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: The Swiss HIV Cohort Study
    • Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003; 163:2187-2195.
    • (2003) Arch Intern Med. , vol.163 , pp. 2187-2195
    • Kaufmann, G.R.1    Perrin, L.2    Pantaleo, G.3
  • 22
    • 0041326880 scopus 로고    scopus 로고
    • Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy
    • Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS. 2003;17:1907-1915.
    • (2003) AIDS , vol.17 , pp. 1907-1915
    • Hunt, P.W.1    Deeks, S.G.2    Rodriguez, B.3
  • 23
    • 22544453346 scopus 로고    scopus 로고
    • Characteristics, determinants, and clinical relevance of CD4 T cell recovery to,500 cells/mL in HIV type 1-infected individuals receiving potent antiretroviral therapy
    • Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to,500 cells/mL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005;41:361-372.
    • (2005) Clin Infect Dis. , vol.41 , pp. 361-372
    • Kaufmann, G.R.1    Furrer, H.2    Ledergerber, B.3
  • 24
    • 2542496096 scopus 로고    scopus 로고
    • Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count
    • Garcia F, de Lazzari E, Plana M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr. 2004;36:702-713.
    • (2004) J Acquir Immune Defic Syndr. , vol.36 , pp. 702-713
    • Garcia, F.1    De Lazzari, E.2    Plana, M.3
  • 25
    • 0035362495 scopus 로고    scopus 로고
    • Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy
    • Tarwater PM, Margolick JB, Jin J, et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:168-175.
    • (2001) J Acquir Immune Defic Syndr. , vol.27 , pp. 168-175
    • Tarwater, P.M.1    Margolick, J.B.2    Jin, J.3
  • 26
    • 0033528735 scopus 로고    scopus 로고
    • Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA study
    • Miller V, Mocroft A, Reiss P, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med. 1999;130:570-577.
    • (1999) Ann Intern Med. , vol.130 , pp. 570-577
    • Miller, V.1    Mocroft, A.2    Reiss, P.3
  • 27
    • 2442711053 scopus 로고    scopus 로고
    • Accounting for leadtime in cohort studies: Evaluating when to initiate HIV therapies
    • Cole SR, Li R, Anastos K, et al. Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies. Stat Med. 2004;23:3351-3363.
    • (2004) Stat Med. , vol.23 , pp. 3351-3363
    • Cole, S.R.1    Li, R.2    Anastos, K.3
  • 28
    • 0042830231 scopus 로고    scopus 로고
    • When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies
    • Phillips AN, Lepri AC, Lampe F, et al. When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS. 2003;17:1863-1869.
    • (2003) AIDS , vol.17 , pp. 1863-1869
    • Phillips, A.N.1    Lepri, A.C.2    Lampe, F.3
  • 29
    • 13444267665 scopus 로고    scopus 로고
    • Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy
    • Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352:570-585.
    • (2005) N Engl J Med. , vol.352 , pp. 570-585
    • Sanders, G.D.1    Bayoumi, A.M.2    Sundaram, V.3
  • 30
    • 13444270732 scopus 로고    scopus 로고
    • Expanded screening for HIV in the United States - An analysis of cost-effectiveness
    • Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States - an analysis of cost-effectiveness. N Engl J Med. 2005;352:586-595.
    • (2005) N Engl J Med. , vol.352 , pp. 586-595
    • Paltiel, A.D.1    Weinstein, M.C.2    Kimmel, A.D.3
  • 31
    • 33644835815 scopus 로고    scopus 로고
    • Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: Comparison between lowincome and high-income countries
    • Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between lowincome and high-income countries. Lancet. 2006;367:817-824.
    • (2006) Lancet , vol.367 , pp. 817-824
    • Braitstein, P.1    Brinkhof, M.W.2    Dabis, F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.